Sanofi SA

Press Release: Sanofi Q2 - strong performance with 10% sales growth; 2024 guidance upgraded

25 Jul 2024 01:30:00 By Nasdaq GlobeNewswire

Sanofi: Information concerning the total number of voting rights and shares – June 2024

22 Jul 2024 16:05:35 By Nasdaq GlobeNewswire

Press Release: NEJM publishes ALTUVIIIO XTEND-Kids phase 3 data supporting its potential to transform the treatment landscape for children with severe hemophilia A

17 Jul 2024 17:27:35 By Nasdaq GlobeNewswire

Press Release: Dupixent approved in the EU as the first-ever targeted therapy for patients with COPD

03 Jul 2024 01:00:00 By Nasdaq GlobeNewswire

Press Release: Dupixent positive phase 3 data in children one to 11 years of age with eosinophilic esophagitis published in NEJM

26 Jun 2024 17:30:00 By Nasdaq GlobeNewswire

Press Release: Availability of the Q2 2024 Aide-mémoire

25 Jun 2024 13:32:52 By Nasdaq GlobeNewswire

Press Release: Audrey Duval Derveloy appointed Global Head of Corporate Affairs, member of Sanofi’s Executive Committee

21 Jun 2024 03:30:00 By Nasdaq GlobeNewswire

Press Release: ISTH: Sanofi advances leadership in hemophilia with new data for ALTUVIIIO and fitusiran

21 Jun 2024 01:00:00 By Nasdaq GlobeNewswire

Press Release: Sanofi and Biovac spearhead polio vaccine manufacturing capabilities in Africa

20 Jun 2024 08:00:00 By Nasdaq GlobeNewswire

Sanofi: Information concerning the total number of voting rights and shares – May 2024

12 Jun 2024 14:19:27 By Nasdaq GlobeNewswire

Press Release: ASCO: Sarclisa is first anti-CD38 to significantly improve progression-free survival in combination with VRd for newly diagnosed transplant-ineligible multiple myeloma in phase 3

03 Jun 2024 16:15:00 By Nasdaq GlobeNewswire

Press Release: Sanofi launches 2024 global Employee Stock Purchase Plan

31 May 2024 06:00:00 By Nasdaq GlobeNewswire

Press Release: Dupixent recommended for EU approval by the CHMP to treat patients with COPD

31 May 2024 01:05:00 By Nasdaq GlobeNewswire

Press Release: Update on FDA priority review of Dupixent for the treatment of COPD patients with type 2 inflammation

31 May 2024 01:00:00 By Nasdaq GlobeNewswire

Press Release: Sanofi completes acquisition of Inhibrx, Inc.

30 May 2024 09:01:34 By Nasdaq GlobeNewswire

Press Release: Sarclisa accepted for FDA priority review for the treatment of transplant-ineligible newly diagnosed multiple myeloma

27 May 2024 01:00:00 By Nasdaq GlobeNewswire

Press Release: Sanofi, Formation Bio and OpenAI announce first-in-class AI collaboration

21 May 2024 01:30:00 By Nasdaq GlobeNewswire

Sanofi: Information concerning the total number of voting rights and shares - April 2024

20 May 2024 16:54:33 By Nasdaq GlobeNewswire

Press Release: Dupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ATS and published in NEJM

20 May 2024 14:15:00 By Nasdaq GlobeNewswire

Press Release: Sanofi adds over €1 billion for biomanufacturing to €2.5 billion already committed in major projects in France to support health sovereignty

13 May 2024 01:00:00 By Nasdaq GlobeNewswire